Tamoxifen therapy benefit for patients with 70-gene signature high and low risk-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Tamoxifen therapy benefit for patients with 70-gene signature high and low risk

Published:2017-08-04 Issue:2 Volume:166 Page:593-601
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

van ‘t Veer Laura J.,Yau Christina,Yu Nancy Y.,Benz Christopher C.,Nordenskjöld Bo,Fornander Tommy,Stål Olle,Esserman Laura J.,Lindström Linda Sofie

Funder

California Breast Cancer Research Program

Breast Cancer Research Fund

Swedish Research Council

Forte

Stiftelsen Gosta Miltons Donationsfund

Stockholm Cancer Society - Cancerforeningen i Stockholm

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/article/10.1007/s10549-017-4428-9/fulltext.html

Reference25 articles.

1. Colleoni M, Sun Z, Price KN et al (2016) Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the international breast cancer study group trials I to V. J Clin Oncol 34:927–935

2. Early Breast Cancer Trialists’ Collaborative Group, Davies C, Godwin J et al (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378:771–784

3. Schiavon G, Smith IE (2014) Status of adjuvant endocrine therapy for breast cancer. Breast Cancer Res 16:206

4. Jirstrom K, Ryden L, Anagnostaki L et al (2005) Pathology parameters and adjuvant tamoxifen response in a randomized premenopausal breast cancer trial. J Clin Path 58:1135–1142

5. Sheppard VB, Faul LA, Luta G et al (2014) Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901. J Clin Oncol 32:2318–2327

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial;Journal of Clinical Oncology;2024-07-24

2. Gene Expression Assays to Tailor Adjuvant Endocrine Therapy for HR+/HER2− Breast Cancer;Clinical Cancer Research;2024-04-24

3. Breast cancer: emerging principles of metastasis, adjuvant and neoadjuvant treatment from cancer registry data;Journal of Cancer Research and Clinical Oncology;2022-12-20

4. Copy number heterogeneity identifies ER+ breast cancer patients that do not benefit from adjuvant endocrine therapy;British Journal of Cancer;2022-07-21

5. Firmas génicas en el cáncer de mama;Revista de Senología y Patología Mamaria;2022-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3